### Guideline Page and Request

<table>
<thead>
<tr>
<th>Guideline Page and Request</th>
<th>Panel Discussion</th>
<th>References</th>
<th>Institutional Vote</th>
</tr>
</thead>
</table>
| NSCL-2, NSCL-5, NSCL-6, NSCL-8, NSCL-11, NSCL-12, NSCL-E Internal request: | Based upon review of the data in the noted references, the panel consensus was to add durvalumab as a treatment option for locally advanced, unresectable NSCLC in patients whose disease has not progressed following platinum-based chemoradiation therapy. | • Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer [article and supplementary appendix published online ahead of print September 8, 2017]. N Engl J Med 2017.  
• Paz-Ares L, Villegas A, Daniel D, et al. PACIFIC: A double-blind, placebo-controlled Phase III study of durvalumab after chemoradiation therapy in patients with stage III, locally advanced, unresectable NSCLC [presentation]. Presented at: European Society of Medical Oncology (ESMO) Annual Meeting; September 8-12, 2017; Madrid, Spain | Yes: 21  
No: 2  
Abstain: 2  
Absent: 2 |
| Internal request: Review the data for the use of durvalumab for the treatment of locally advanced, unresectable NSCLC in patients whose disease has not progressed following platinum-based chemoradiation therapy. |  |  |  |
| NSCL-18 Internal request: | Based upon review of the data in the noted references, the panel consensus was to add osimertinib as an option for the first-line treatment of metastatic EGFR mutation-positive NSCLC. This is a category 2A recommendation. | • Ramalingam SS, Reungwetwattana T, Chewaskulyong B, et al. Osimertinib vs standard-of-care EGFR-TKI as first-line treatment in patients with EGFRm advanced NSCLC: FLAURA [presentation]. Presented at: European Society of Medical Oncology (ESMO) Annual Meeting; September 9-12, 2017; Madrid, Spain.  
No: 2  
Abstain: 2  
Absent: 2 |